Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Early-Stage Cell And Gene Therapy Progress: Updates From Casebia, BlueRock, Athersys, Cynata

Executive Summary

Scrip caught up with several companies during the recent Cell and Gene Meeting on the Mesa, sponsored by the Alliance for Regenerative Medicine.


Related Content

Bayer Bosses Beg Risk-Averse Europe To Rethink
J.P. Morgan Roundtable: The Regulatory Role In Accelerating Complex Therapies
Pipeline Watch: Phase III Starts With Bavencio, MultiStem And VT-1161
US FDA’s Breakthrough And RMAT Designations: A Quick Guide
RMAT Designation Requests May Rise Or Fall On Manufacturing Changes, Clinical Data Breadth
Tech Transfer Roundup: Neon Licenses NKI IP To Advance Cell Therapy Into Clinic
Deal Watch: Celgene The Latest To Buy Into Nimbus’ Computational Chemistry Approach
J.P. Morgan Notebook Day 3: Novartis' Cancer Reorg, AbbVie's Price Pledge, Genentech’s Partnering And More
Cynata Sets Stage For Global Fujifilm Cell Therapy Deal
Chugai Signals Cell Therapy Interest Via Athersys Deal


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts